- Home
- KALV vs ATLC Comparison
KALV vs ATLC Comparison
Compare KALV & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- ATLC
- Stock Information
- Founded
- KALV N/A
- ATLC 1996
- Country
- KALV United States
- ATLC United States
- Employees
- KALV N/A
- ATLC N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- KALV Health Care
- ATLC Finance
- Exchange
- KALV Nasdaq
- ATLC Nasdaq
- Market Cap
- KALV 651.3M
- ATLC 732.1M
- IPO Year
- KALV N/A
- ATLC 1999
- Fundamental
- Price
- KALV $12.92
- ATLC $48.69
- Analyst Decision
- KALV Strong Buy
- ATLC Strong Buy
- Analyst Count
- KALV 8
- ATLC 5
- Target Price
- KALV $24.83
- ATLC $62.00
- AVG Volume (30 Days)
- KALV 498.7K
- ATLC 47.2K
- Earning Date
- KALV 07-10-2025
- ATLC 05-08-2025
- Dividend Yield
- KALV N/A
- ATLC N/A
- EPS Growth
- KALV N/A
- ATLC 21.75
- EPS
- KALV N/A
- ATLC 5.17
- Revenue
- KALV N/A
- ATLC $424,877,000.00
- Revenue This Year
- KALV N/A
- ATLC $270.55
- Revenue Next Year
- KALV N/A
- ATLC $11.94
- P/E Ratio
- KALV N/A
- ATLC $9.40
- Revenue Growth
- KALV N/A
- ATLC 17.71
- 52 Week Low
- KALV $7.30
- ATLC $25.14
- 52 Week High
- KALV $15.50
- ATLC $64.70
- Technical
- Relative Strength Index (RSI)
- KALV 60.56
- ATLC 40.03
- Support Level
- KALV $11.11
- ATLC $48.36
- Resistance Level
- KALV $11.93
- ATLC $49.80
- Average True Range (ATR)
- KALV 0.60
- ATLC 1.86
- MACD
- KALV 0.05
- ATLC -0.48
- Stochastic Oscillator
- KALV 80.09
- ATLC 20.71
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.